Searchable abstracts of presentations at key conferences in endocrinology

ea0009p226 | Clinical | BES2005

An audit on the type and amount of specialist education that newly appionted endocrine nurses receive; educational needs unmet?

Smethurst L , Roberts M

There is an increasing pressure for nurses to have a recognised qualification in their specialist area to be able to use the title 'specialist' nurse. As there is a historical lack of a recognised qualification in endocrinology for nurses, we audited exactly where nurses gained their specialist knowledge in the first year in post.There were no publications on this topic.86 questionnaires designed to allow the individual to rate the...

ea0007p127 | Endocrine tumours and neoplasia | BES2004

24-hour ambulatory blood pressure monitoring (ABPM) in patients with acromegaly and the value of clinic blood pressure measurements

Paisley A , Roberts M , Heagerty A , Trainer P

Cardiovascular outcomes are better predicted by 24 hour ambulatory BP monitoring than random clinic BP (mmHg). In acromegaly, hypertension is common and cardiovascular disease is the principal cause of death. We investigated prevalence and characteristics of hypertension in 44 patients (26 male, mean age 53.1 ± 14.2), 17 of whom were receiving treatment for hypertension. A random clinic BP (normal <140/90) and IGF-I were measured prior to 24 hr ABPM assessment (Astra...

ea0007p126 | Endocrine tumours and neoplasia | BES2004

Improved quality of life (QOL) with normalisation of IGF-I in patients with acromegaly

Paisley A , Rowles S , Roberts M , Lee C , Trainer P

We have previously reported comparisons of ACROQOL, a disease-specific questionnaire for QOL in patients with acromegaly, with the non-disease-specific generic tools Psychological General Well-Being Schedule (PGWBS) and EUROQOL and disease-specific signs and symptoms score (SSS). ACROQOL comprises 22 questions (subdivided into physical and psychological classes, total score out of 110 quoted as percentage, higher scores = better QOL). SSS rates 5 features of acromegaly each ra...

ea0007p224 | Steroids | BES2004

Reproducibility of cortisol day curve in monitoring patients on long-term Hydrocortisone Replacement Therapy

Shakoor S , Roberts M , Shalet S , Trainer P

The risks of over and under-replacement with glucocorticoid replacement therapy are well-known. In an attempt to minimise these risks cortisol day curves (CDC) are performed in many centres, however there is a dearth of data on the reproducibility of this assessment and the relationship between symptoms and serum cortisol levels. To address these issues, we have performed 2 cortisol day curves within 7 days in 20 patients (9 male, mean age 54 years, range 25-79, 6 primary and ...

ea0006p40 | Endocrine tumours and neoplasia | SFE2003

The effect of pegvisomant therapy on plasma levels of matrix metalloproteinases 2, 9 and vascular endothelial growth factor in patients with acromegaly

Paisley A , Randeva H , Parkinson C , Alsafadi H , Roberts M , Monson J , Drake W , Trainer P

Vascular endothelial growth factor (VEGF) is involved in the activation of the matrix metalloproteinase system (MMP) which in turn degrades the extracellular matrix involved in development, morphogenesis and tissue remodelling. Increased activity of MMPs has been implicated in atherosclerosis and cardiovascular disease. This study assessed plasma MMP and VEGF levels in patients with active acromegaly (IGF-I >130%ULN), and on treatment with pegvisomant.<p class="abstext"...

ea0005p178 | Neuroendocrinology and Behaviour | BES2003

Insulin sensitivity improves in patients with acromegaly converted from depot octreotide (Sandostatin LAR) to pegvisomant

Drake W , Rowles S , Roberts M , Fode F , Besser G , Monson J , Trainer P

Pegvisomant is a novel medical therapy for acromegaly that functions as a GH receptor antagonist. Insulin resistance is an important factor in the increased cardiovascular morbidity and mortality associated with acromegaly. The aim of this study was to compare insulin sensitivity (IS) in a group of 7 patients with acromegaly (3 male, mean age 59+/-13 years, SD), treated first with a stable dose of depot octreotide (OT) (median dose 20mg four weekly, range 10-20) for at least t...

ea0003p200 | Neuroendocrinology | BES2002

Disease activity in acromegaly may be assessed four weeks after discontinuation of pegvisomant

Drake W , Loureiro R , Parkinson C , Roberts M , Akker S , Monson J , Besser G , Trainer P

Patients with acromegaly treated with medical therapy intermittently discontinue therapy to allow assessment of underlying disease activity. This is particularly so in patients treated with pituitary irradiation. Typical 'washout' times include 5 weeks for bromocriptine and 2 weeks for short-acting sc octreotide; longer periods are required for cabergoline and slow-release somatostatin analogues. Pegvisomant is a novel medical therapy for acromegaly that functions as a GH rece...